Skip to main content

Advertisement

Table 1 Comparison of baseline characteristics

From: Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

  FOLFOX4 (EACH) Sorafenib (ORIENTAL)
n % n %
N 184   150  
Age 49.53 (mean) 51 (median)
Male 166 90.2 127 81.7
HBV infection 171 92.9 106 70.7
HCV infection 9 4.9 16 10.7
Child–Pugh stage
 A 163 88.6 146 97.3
 B 21 11.4 4 2.7
BCLC stage
 B 39 21.2   
 C 145 78.8 143 95.3
Extrahepatic spread 104 56.5 103 68.7